XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:    
Net loss $ (4,234,742) $ (3,056,039)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation and amortization 1,893,602 1,943,000
Interest from amortization of loan issuance costs 120,833 0
Loss on disposal of property and equipment 78,437 0
Stock-based compensation on stock options, RSUs & RSAs, net 506,020 551,853
Provision for credit losses 0 2,236
Change in operating lease assets and liabilities (57,653) 80,355
Inventory write-offs to allowance 135,625 73,569
Deferred taxes (2,795) 9,395
Changes in operating assets and liabilities:    
Trade accounts receivable (350,703) 1,717,283
Other current assets 41,286 (191,381)
Inventories (13,005) 54,461
Prepaid expenses and deposits (123,598) 94,619
Accounts payable and accrued liabilities (430,923) (424,310)
Net cash provided by (used in) operating activities (2,437,616) 850,569
Cash flows from investing activities:    
Purchase of property and equipment (160,155) (1,484,401)
Proceeds from sale of equipment 10,648 0
Proceeds from sale-leaseback of equipment 0 364,710
Acquisition of Visimid Technologies, net of cash acquired 0 (722,141)
Net cash used in investing activities (149,507) (1,841,832)
Cash flows from financing activities:    
Proceeds from sale of common stock from Employee Stock Purchase Plan 10,372 19,719
Deferred payment for acquisition of Visimid (125,000) 0
Loan issuance costs (300,000) 0
Borrowings on loans payable 3,000,000 142,853
Payments on loans payable (106,486) (407,510)
Repayment of finance lease obligations (89,705) (58,785)
Net cash (used in) provided by financing activities 2,389,181 (303,723)
Effect of exchange rate on cash and cash equivalents (81,260) 32,698
Change in cash, cash equivalents and restricted cash (279,202) (1,262,288)
Cash, cash equivalents and restricted cash, beginning of period 3,480,268 7,144,490
Cash, cash equivalents and restricted cash, end of period 3,201,066 5,882,202
Supplemental disclosure of cash flow information:    
Interest paid in cash 40,838 110,774
Income taxes paid 61,427 114,953
Supplemental disclosure of non-cash investing & financing activities:    
Purchase of equipment through finance lease arrangements 93,048 61,654
Issuance of common stock for acquisition of Visimid $ 321,358 $ 150,000